Sunovian Pharmaceuticals’ Kynmobi will address unmet need in the Parkinson’s treatment market

26 May 2020 (Last Updated May 26th, 2020 10:16)

Last week, Sunovion Pharmaceuticals announced it secured the Food and Drug Administration (FDA) approval for its Parkinson's Disease treatment, Kynmobi. Effective treatment for off episodes and dyskinesia remains an ongoing challenge in Parkinson's as over half of the affected patients will eventually have off periods.

Episodes experienced by Parkinson's patients occur when the standard of care therapy levodopa wears off, which results in a worsening of symptoms such as tremors and rigidity. Read more here.